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Available online 4 January 2018Parkinson's disease (PD) is a neurodegenerative disease with unknown etiology. Here we show the gener-
ation of an induced pluripotent stem cell (iPSC) line, named CSC-40, from dermal ﬁbroblasts obtained from
a 59-year-old male patient with a homozygous p.Q456X mutation in the PTEN-induced putative kinase 1
(PINK/PARK6) gene and a conﬁrmed diagnosis of PD, which could be used to model familial PD. A non-inte-
grating Sendai virus-based delivery of the reprogramming factors OCT3/4, SOX2, c-MYC and KLF4 was
employed. The CSC-40 cell line showed normal karyotyping and ﬁngerprinting following transduction as
well as sustained expression of several pluripotency markers and the ability to differentiate into all three
germ layers..
en access article© 2018 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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(Valente et al., 2001). The CSC-40 induced pluripotent stem cell
(iPSC) line, with a mutation in the PINK1 gene, allows investigations
of familial PD cells for disease modeling and potential therapeutic
explorations.Fig. 1. Characterization ofResource details
The PINK1 protein together with PARKIN can initiate the
ubiquitination and removal of the damaged mitochondrion (Geisler et
al., 2010). Mutation in PINK1 is linked to early-onset recessive PDthe iPSC line CSC-40F.
63K. Russ et al. / Stem Cell Research 27 (2018) 61–64(Valente et al., 2001). Herewe report the generation of a novel iPSC line,
named CSC-40, from dermal ﬁbroblasts obtained from a 59-year-old
male PD patient with a homozygous p.Q456X mutation in PINK1.
Reprograming of patient ﬁbroblasts was done using non-integration
Sendai virus to deliver the reprograming factors OCT3/4, SOX2, c-MYC
and KLF4 to the cells. Three clones (CSC-40F, CSC-40I and CSC-40G)
were selected based on the morphology of the colonies, and character-
ized as previously described (Holmqvist et al., 2016). Here, we report
the characterization of the clone CSC-40F.
The generated CSC-40F line stained positive for the common nuclear
and cell surface pluripotency markers, OCT4, NANOG, TRA1-81 and
SSEA4 (Fig. 1A–F). Flow cytometry analysis showed that N98% of the
iPSCs were positive for SSEA4 (Fig. 1H; non-stained iPSCs are shown
in grey). An alkaline phosphatase staining further conﬁrmed the
pluripotency of CSC-40F iPSC line (Fig. 1G). The CSC-40F line was clear
of Sendai virus by passage 7 (Fig. 1I) and showed normal karyotyping
(Fig. 1J). Genetic integrity was conﬁrmed by ﬁngerprint analysis of iso-
latedDNA fromboth patient ﬁbroblasts and CSC-40F iPSC line, while the
presence of the homozygous p.Q456X mutation was detected by DNA
sequencing (Fig. 1K). Finally, CSC-40F iPSC line was cultured as embry-
oid bodies (EBs) and then plated onto a 96-well plate to demonstrate its
ability to differentiate into each of the three germ layers, in vitro. Immu-
nocytochemistry revealed the expression of ectodermalmarker beta-III-
tubulin (BIIItub), the mesodermal marker smooth muscle actin (SMA),
and the endodermal marker alpha-fetoprotein (AFP; Fig. 1L–O).
Plasmocin was used during the reprogramming and early passages as
prophylactic dose to prevent Mycoplasma (Table 1).
Materials and methods
Collection and reprogramming of patient's ﬁbroblasts
Induced PSCs were generated from human dermal ﬁbroblasts, har-
vested using a skin punch biopsy, from patientwith a conﬁrmed clinical
diagnosis of PD. Patient ﬁbroblasts were cultured and expanded in
Dulbecco's modiﬁed eagle's medium (DMEM) supplemented with 10%
fetal bovine serum and 1% Penicillin-Streptomycin (v/v, all
ThermoFisher Scientiﬁc) at 37 °C and 5% CO2 for several passages before
being cryopreserved and stored at−150 °C.
For reprogramming, ﬁbroblasts were thawed and plated on a 0.1%
gelatin-coated 12-well plate at a concentration of 75,000 per well.
Two days after, the cells were transduced with OCT3/4, SOX2, c-MYC
and KLF4 reprogramming factors using CytoTune™-iPS 2.0 Sendai
reprogramming kit according to manufacturer's instructions
(ThermoFisher Scientiﬁc). Fibroblast growth media was changed
every other day for 7 days following transduction. At day 7, theTable 1
Characterization and validation.
Classiﬁcation Test Result
Morphology Photography Visual record of the line: normal
Phenotype Immunocytochemistry Positive staining for pluripotency
Flow cytometry 98.9% SSEA4
Alkaline phosphatase
activity
Visible activity
Genotype Karyotype (G-banding)
and resolution
46,XY, (300–400 bands resolution
Identity STR analysis 10 sites analyzed, all matched wi
Mutation analysis Sequencing homozygous p.Q456X mutation i
Microbiology and
virology
Mycoplasma Mycoplasma testing by RT-PCR. N
Differentiation potential Embryoid body formation Positive staining for smooth mus
spontaneous differentiation of em
Donor screening
(OPTIONAL)
HIV 1 + 2 Hepatitis B,
Hepatitis C
N/A
Genotype additional info
(OPTIONAL)
Blood group genotyping N/A
HLA tissue typing N/Aﬁbroblasts were passaged using 0.05% trypsin-EDTA (Sigma-Aldrich)
and plated onto irradiated mouse embryonic ﬁbroblasts feeder cells
(CF-1 MEF, GlobalStem) with WiCell media composed of advanced
DMEM/F12 (Thermo Fisher Scientiﬁc), 20% Knock-Out Serum Replace-
ment (v/v, ThermoFisher Scientiﬁc), 2 mM L-glutamine (Thermo Fisher
Scientiﬁc), 1% non-essential amino acids (NEAA, v/v, Millipore), 0.1mM
β-mercaptoethanol (Sigma-Aldrich) and 20 ng/ml FGF2 (ThermoFisher
Scientiﬁc). At day 28, single colonies were manually picked and re-
seeded separately onto a ﬁbroblast feeder cell-coated 12-well plate. In-
dividual clones were passaged using dispase (ThermoFisher Scientiﬁc)
weekly with media changed daily. Cells were then frozen in WiCell
media and freezing media (20% DMSO + FBS 80%) 1:1 with 10 μM
Rock inhibitor (Sigma-Aldrich) and stored at−150 °C.
Alkaline phosphatase activity
Alkaline phosphatase staining was completed using the Alkaline
Phosphatase Staining Kit according to manufacturer's protocol
(Stemgent, MA).
Karyotyping
The G-banding analysis was performed at 300–400 band resolution
in average after 14 passages at the Department of Clinical Genetics
and Pathology in Lund.
Mutation sequencing and ﬁngerprint analysis
The mutation p.Q456X in PINK1, was conﬁrmed by direct DNA se-
quencing (Macrogen Europe, Amsterdam, The Netherlands) following
DNA isolation using a lysis buffer (100 mM Tris (pH 8.0), 200 mM
NaCl, 5 mM EDTA, and 0.2% SDS in distilled and autoclaved water sup-
plementedwith 1.5mg/ml Proteinase K). Primers used for ampliﬁcation
and directed sequencing of PINK around the mutation site are listed in
the Table 2. To conﬁrm the genetic integrity of theDNA between patient
ﬁbroblasts and iPSCs, DNAwas isolated and sent to IdentiCell STR proﬁl-
ing service (Department of MolecularMedicine, Aarhus University Hos-
pital, Denmark).
In vitro differentiation
For spontaneous differentiation, iPSCs were grown as EBs for
2 weeks on ultra low-attachment 24-well plates (Corning) with WiCell
media. At the end of 2 weeks, EBs were dissociated and plated onto ad-
herent 96-well plates (Greiner Bio-One) coated with 0.1% gelatin
(Millipore) in DMEM supplemented with 10% fetal bovine serum andData
Not shown but
available with author
markers OCT4, NANOG, TRA1–81, SSEA4. Fig. 1 panel A-F
Fig. 1 panel H
Fig. 1 panel G
in average) Fig. 1 panel J
th ﬁbroblasts from the original donor Available with author
n PINK1 Fig. 1 panel K
egative. Not shown but
available with author
cle actin, beta-III-tubulin and alpha-fetoprotein after
bryoid bodies
Fig. 1 panel L-O
N/A
N/A
N/A
Table 2
Reagents details.
Antibodies used for immunocytochemistry
Antibody Dilution Company Cat # and RRID
Pluripotency Markers Mouse anti-OCT4 1:200 Millipore Cat# MAB4401, RRID:AB_2167852
PE-conjugated mouse anti-human NANOG 1:200 BD Biosciences Cat# 560483, RRID:AB_1645522
Mouse anti- TRA-1-81 1:200 Thermo Fisher Scientiﬁc Cat# 41–1100, RRID:AB_2533495
PE-conjugated mouse anti-SSEA4 1:200 Thermo Fisher Scientiﬁc Cat# A14766, RRID:AB_2534281
Sendai Chicken anti-Sendai virus 1:1000 Abcam Cat# ab33988, RRID:AB_777877
Differentiation Markers Mouse anti-AFP 1:200 Sigma-Aldrich Cat# A8452, RRID:AB_258392
Mouse anti-SMA 1:200 Sigma-Aldrich Cat# A2547, RRID:AB_476701
Mouse anti-beta-III tubulin 1:200 Sigma-Aldrich Cat# T8660, RRID:AB_477590
Secondary antibodies Donkey anti-mouse Alexa Fluor® 488 1:400 Molecular Probes Cat# A-21202, RRID:AB_141607
Donkey anti-chicken Alexa Fluor® 488 1:400 Jackson ImmunoResearch Labs Cat# 703-545-155, RRID:AB_2340375
Donkey anti-mouse Alexa Fluor® 555 1:400 Thermo Fisher Scientiﬁc Cat# A-31570, RRID:AB_2536180
Primers
Target Forward/Reverse primer (5′–3′)
Mutation sequencing PINK1 TGGATCAGGTGATGTGCAGGA/
AGGATCTGTCACTGTGGCTCT
64 K. Russ et al. / Stem Cell Research 27 (2018) 61–641% Penicillin-Streptomycin. iPSCs were cultured for 2 additional weeks
with media changed every 2 days before being stained with antibodies
against BIIItub, SMA, and AFP.
Immunocytochemistry
For immunocytochemical analysis, iPSCs were ﬁxed with 4% PFA for
10 min at RT followed by standard immunocytochemical procedures.
Blocking was done in 10% donkey serum in PBS with 0.1% Triton-X100
(Sigma-Aldrich) for 1 h at RT. Primary antibodies, listed in the Table 2,
were then added to the cells and incubated overnight at 4 °C. Next the
secondary antibodies, listed in the Table 2, were added and incubated
for 1 h at RT in the dark. Additionally, nuclei were stained by DAPI
(1:10,000; Life Technologies). All ﬂuorescent photomicrographs were
taken using an inverted epiﬂuorescence microscope (LRI - Olympus
IX-73). Scale bars are 200μm.
Mycoplasma detection
Absence of mycoplasma contamination was conﬁrmed by the real-
time PCRmethod at GATC Biotech AG (European Genome and Diagnos-
tics Centre, Konstanz, Germany).
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